A major step forward in the treatment of accelerated aging

In a study published in the journal EMBO Molecular Medicine, the team led by Professor Nicolas Lévy identifies the mechanism linked to the accumulation of progerin, a toxic protein produced during aging, and demonstrates the therapeutic potential of the MG132 molecule to treat progeria, a rare syndrome of premature and accelerated aging.

Nicolas Lévy and his team have demonstrated the ability of this molecule to significantly reduce the production of progerin and simultaneously degrade it. In addition to its use in the fight against Progeria, this molecule, like other compounds of the same family, are currently being evaluated for the treatment of other rare diseases such as more frequent diseases and certain cancers.

This work, supported by Aix-Marseille University, the A*Midex Foundation, Inserm and AFM-Téléthon, opens the way for a therapeutic trial and the development of compounds to combat the effects of accelerated and physiological aging.